Ontology highlight
ABSTRACT:
SUBMITTER: Siddiqi T
PROVIDER: S-EPMC6982547 | biostudies-literature | 2020 Feb
REPOSITORIES: biostudies-literature
Leukemia & lymphoma 20191016 2
Alisertib, an Aurora kinase A inhibitor, was evaluated in a Phase 1 study in combination with the histone deacetylase inhibitor vorinostat, in patients with relapsed/refractory lymphoid malignancies (<i>N</i> = 34; NCT01567709). Patients received alisertib plus vorinostat in 21-day treatment cycles with escalating doses of alisertib following a continuous or an intermittent schedule. All dose-limiting toxicities (DLTs) were hematologic and there were no study-related deaths. The recommended phas ...[more]